LexDanaLexDanabeta
Inventor

Tao Guo

Inventor
Dayton, NJ, US

Overview

49→
Patents
1999–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 49 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
A61KPreparations for medical, dental or toiletry purposes15%
C07CAcyclic or carbocyclic compounds4%
Y02ATechnologies for adaptation to climate change3%
C04BLime, magnesia2%
H01LSemiconductor devices2%
H10KOrganic electric solid-state devices2%
B32BLayered products, i.e. products built-up of strata of flat or non-flat, e.g. cellular or honeycomb, form1%
C07KPeptides1%
PatentTitleYear
11,046,653Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof202110,991,911Package structure, packaging method and electronic device202110,985,346OLED display device and manufacturing method thereof202110,294,215Therapeutically active compounds and their methods of use201910,166,201Substituted hydroxystilbenes and their therapeutic applications201910,017,495Therapeutically active compounds and their methods of use20189,732,062'Therapeutically active compounds and their methods of use'20179,725,406'Substituted hydroxystilbenes and their therapeutic applications'20179,656,999'Therapeutically active compounds and their methods of use'20179,512,107'Therapeutically active compositions and their methods of use'20169,243,002'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C'20169,200,323'Hybridization methods using natural base mismatches'20159,062,007'Cyclic amide BACE-1 inhibitors having a benzamide substituent'20158,937,093'Heterocyclic aspartyl protease inhibitors'20158,906,911'Chemokine receptor antagonists'20148,871,756'Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease'20148,829,036'Heterocyclic aspartyl protease inhibitors'20148,778,980'Heterocyclic aspartyl protease inhibitors'20148,722,708'Substituted isoindolines as aspartyl protease inhibitors'20148,691,833'Heterocyclic aspartyl protease inhibitors'20148,691,831'Heterocyclic aspartyl protease inhibitors'20148,623,867'Cyclic amine BACE-1 inhibitors having a benzamide substituent'20148,552,186'Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors'20138,513,232'Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands'20138,436,183'Synthetic multimerizing agents'20138,278,334'Cyclic amine BACE-1 inhibitors having a benzamide substituent'20128,242,112'Heterocyclic aspartyl protease inhibitors'20128,178,513'Heterocyclic aspartyl protease inhibitors'20128,148,391'Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors'20128,106,191'Synthetic multimerizing agents'20127,973,067'Heterocyclic aspartyl protease inhibitors'20117,763,609'Heterocyclic aspartyl protease inhibitors'20107,759,353'Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment'20107,700,603'Heterocyclic aspartyl protease inhibitors'20107,662,816'Cyclic amine BACE-1 inhibitors having a benzamide substituent'20107,598,250'Cyclic amine BACE-1 inhibitors having a heterocyclic substituent'20097,592,348'Heterocyclic aspartyl protease inhibitors'20097,550,467'Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20097,511,146'2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20097,256,186'Gamma secretase inhibitors'20077,208,602'Gamma secretase inhibitors'20077,084,154'2-(aminomethyl) arylamide analgesics'20067,034,056'Aryl and biaryl compounds having MCH modulatory activity'20066,900,213'Bisaryl derivatives having FSH modulatory activity'20056,887,889'Aryl and biaryl piperdines with MCH modulatory activity'20056,218,551'Combinatorial hydroxy-amino acid amide libraries'20016,150,527'Synthetic multimerizing agents'20006,133,456'Synthetic multimerizing agents'20005,972,719'Combinatorial hydroxy-amino acid amide libraries'1999

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2001Based in Somerset, NJ, US· patent location history
2005–2015Patents assigned to PHARMACOPEIA DRUG DISCOVERY (11)· patent assignee history
2005–2019Based in Dayton, NJ, US· patent location history
2007–2012Patents assigned to SCHERING CORP (12)· patent assignee history
2012–2015Patents assigned to GUO TAO (17)· patent assignee history
2012–2016Patents assigned to MERCK SHARP & DOHME (9)· patent assignee history
2012–2015Patents assigned to SAIONZ KURT W (9)· patent assignee history
2014–2021Based in Shanghai, CN· patent location history
2017–2019Based in Tianjin, CN· patent location history
2021Based in Shenzhen, CN· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GUO TAOself172012–2015
SCHERING CORP122007–2012
PHARMACOPEIA DRUG DISCOVERY112005–2015
MERCK SHARP & DOHME92012–2016
SAIONZ KURT W92012–2015
Locations
LocationPatentsSpan
Dayton, New Jersey, US362005–2019
Shanghai, CN42014–2021
Somerset, New Jersey, US41999–2001
Tianjin, CN22017–2019
Shenzhen, CN12021